| 000 | 01737 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515030954.0 | ||
| 264 | 0 | _c20061006 | |
| 008 | 200610s 0 0 eng d | ||
| 022 | _a0960-894X | ||
| 024 | 7 |
_a10.1016/j.bmcl.2006.05.072 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSabat, Mark | |
| 245 | 0 | 0 |
_aThe development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck). _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _cAug 2006 |
||
| 300 |
_a4257-61 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aDrug Industry _xmethods |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 |
_aLymphocyte Specific Protein Tyrosine Kinase p56(lck) _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aLymphocytes _xmetabolism |
| 650 | 0 | 4 | _aModels, Chemical |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 |
_aPyridazines _xchemistry |
| 650 | 0 | 4 |
_aPyrimidines _xchemistry |
| 650 | 0 | 4 |
_aRibonucleosides _xchemistry |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aVanrens, John C | |
| 700 | 1 | _aBrugel, Todd A | |
| 700 | 1 | _aMaier, Jennifer | |
| 700 | 1 | _aLaufersweiler, Matthew J | |
| 700 | 1 | _aGolebiowski, Adam | |
| 700 | 1 | _aDe, Biswanath | |
| 700 | 1 | _aEaswaran, Vijayasurian | |
| 700 | 1 | _aHsieh, Lily C | |
| 700 | 1 | _aRosegen, Jeff | |
| 700 | 1 | _aBerberich, Steve | |
| 700 | 1 | _aSuchanek, Eric | |
| 700 | 1 | _aJanusz, Michael J | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 16 _gno. 16 _gp. 4257-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmcl.2006.05.072 _zAvailable from publisher's website |
| 999 |
_c16353337 _d16353337 |
||